Hyperinflammation and Fibrosis in Severe COVID-19 Patients : Galectin-3, a Target Molecule to Consider
(2020) In Frontiers in Immunology 11.- Abstract
COVID-19 disease have become so far the most important sanitary crisis in the XXI century. In light of the events, any clinical resource should be considered to alleviate this crisis. Severe COVID-19 cases present a so-called cytokine storm as the most life-threatening symptom accompanied by lung fibrosis. Galectin-3 has been widely described as regulator of both processes. Hereby, we present compelling evidences on the potential role of galectin-3 in COVID-19 in the regulation of the inflammatory response, fibrosis and infection progression. Moreover, we provide a strong rationale of the utility of measuring plasma galectin-3 as a prognosis biomarker for COVID-19 patients and propose that inhibition of galectin-3 represents a feasible... (More)
COVID-19 disease have become so far the most important sanitary crisis in the XXI century. In light of the events, any clinical resource should be considered to alleviate this crisis. Severe COVID-19 cases present a so-called cytokine storm as the most life-threatening symptom accompanied by lung fibrosis. Galectin-3 has been widely described as regulator of both processes. Hereby, we present compelling evidences on the potential role of galectin-3 in COVID-19 in the regulation of the inflammatory response, fibrosis and infection progression. Moreover, we provide a strong rationale of the utility of measuring plasma galectin-3 as a prognosis biomarker for COVID-19 patients and propose that inhibition of galectin-3 represents a feasible and promising new therapeutical approach.
(Less)
- author
- Garcia-Revilla, Juan ; Deierborg, Tomas LU ; Venero, Jose Luis and Boza-Serrano, Antonio LU
- organization
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- biomarker, COVID-19, cytokine storm, fibrosis, galectin-3
- in
- Frontiers in Immunology
- volume
- 11
- article number
- 2069
- publisher
- Frontiers Media S. A.
- external identifiers
-
- scopus:85090049774
- pmid:32973815
- ISSN
- 1664-3224
- DOI
- 10.3389/fimmu.2020.02069
- language
- English
- LU publication?
- yes
- id
- 11bfea5e-9eb4-4a01-b564-097e76406f44
- date added to LUP
- 2020-09-25 15:02:00
- date last changed
- 2024-09-20 05:10:22
@article{11bfea5e-9eb4-4a01-b564-097e76406f44, abstract = {{<p>COVID-19 disease have become so far the most important sanitary crisis in the XXI century. In light of the events, any clinical resource should be considered to alleviate this crisis. Severe COVID-19 cases present a so-called cytokine storm as the most life-threatening symptom accompanied by lung fibrosis. Galectin-3 has been widely described as regulator of both processes. Hereby, we present compelling evidences on the potential role of galectin-3 in COVID-19 in the regulation of the inflammatory response, fibrosis and infection progression. Moreover, we provide a strong rationale of the utility of measuring plasma galectin-3 as a prognosis biomarker for COVID-19 patients and propose that inhibition of galectin-3 represents a feasible and promising new therapeutical approach.</p>}}, author = {{Garcia-Revilla, Juan and Deierborg, Tomas and Venero, Jose Luis and Boza-Serrano, Antonio}}, issn = {{1664-3224}}, keywords = {{biomarker; COVID-19; cytokine storm; fibrosis; galectin-3}}, language = {{eng}}, publisher = {{Frontiers Media S. A.}}, series = {{Frontiers in Immunology}}, title = {{Hyperinflammation and Fibrosis in Severe COVID-19 Patients : Galectin-3, a Target Molecule to Consider}}, url = {{http://dx.doi.org/10.3389/fimmu.2020.02069}}, doi = {{10.3389/fimmu.2020.02069}}, volume = {{11}}, year = {{2020}}, }